PXMTF.US PHAXIAM Therapeutics S.A.

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 17, 2026
0.0001 0.0001
Market cap
USD 1.01K
P/E
-
P/B
-
ROE
-1.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is PXMTF.US undervalued?

Graham number

The Graham number of PHAXIAM Therapeutics S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PHAXIAM Therapeutics S.A. fundamental analysis

No fundamental analysis for PHAXIAM Therapeutics S.A. yet.

PHAXIAM Therapeutics S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus)…

Full company profile